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T cell-dependent bispecific antibodies
(TDBs). They develop a TDB targeting
FcRH5 expressed in all multiple myeloma
tumor cells and show its potential in
treating this disease.
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http://dx.doi.org/10.1016/j.ccell.2017.02.001SUMMARYThe anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5
expressed inmultiplemyeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation
by inducing target clustering and exclusion of CD45 phosphatase from the synapse. The dimensions of the
target molecule play a key role in the efficiency of the synapse formation. The anti-FcRH5/CD3 TDB kills
human plasma cells and patient-derived myeloma cells at picomolar concentrations and results in complete
depletion of B cells and bone marrow plasma cells in cynomolgus monkeys. These data demonstrate the po-
tential for the anti-FcRH5/CD3 TDB, alone or in combination with inhibition of PD-1/PD-L1 signaling, in the
treatment of MM and other B cell malignancies.INTRODUCTION
Multiple myeloma (MM) is an incurable malignancy of plasma
cells characterized by dysregulated growth of abnormal plasma
cells in the bone marrow and overproduction of intact mono-
clonal immunoglobulins that ultimately lead to clinical manifesta-
tions including skeletal lesions, renal failure, anemia, and hyper-
calcemia. Currently the backbone of MM treatment involves
combinations of proteasome inhibitors (PIs), immunomodula-
tors, and corticosteroids, with bone marrow transplantation as
an additional option for eligible patients. Newer agents are being
developed for the treatment of MM, including the monoclonal
antibodies targeting CD38 (daratumomab) and SLAMF7 (elotu-
zumab). Nevertheless, despite progressive improvements in
myeloma treatment, the mortality rate remains high and median
survival remains less than 5 years (http://seer.cancer.gov/).
Heterogeneous disease biology and genetics, limited avail-
ability of predictive preclinical models, and a paucity of known
myeloma-specific surface targets remain key challenges inSignificance
Our study describes how CD3-bispecific antibody ‘‘triggers’’ in
the target molecule and epitope location play a key role in the
activation. These findings are important for future design of T c
and preclinically validated an anti-FcRH5/CD3 TDB as an immu
highly efficacious in the killing of myeloma cells and depletes
Cancer Cell 31, 383–395,
This is an open access article undmyeloma drug development. FcRH5 (also known as FcRL5,
IRTA2, or CD307) has been identified as an attractive B cell line-
age-specific surface marker in myeloma (Elkins et al., 2012; Hat-
zivassiliou et al., 2001; Polson et al., 2006). High-affinity ligands
and biological significance of FcRH5 are largely unknown.
FcRH5 is expressed exclusively in the B cell lineage. Expression
is detected as early as pre-B cells (Polson et al., 2006); however,
unlike other B cell-specific surface proteins (e.g., CD20, CD19,
and CD22), FcRH5 expression is retained in plasma cells. Anal-
ogous to its expression in normal plasma cells, FcRH5 is ex-
pressed by myeloma tumor cells. Finally, FcRH5 expression
has been reported in several B cell malignancies (Ise et al.,
2007; Li et al., 2008; Polson et al., 2006), suggesting broader
applicability of this target in hematological malignancies.
Therapies that direct T cells to tumors, including adoptive
transfer of genetically engineered T cells and T cell-dependent
bispecific antibodies (TDBs) that selectively recruit T cells to tu-
mor cells have been clinically validated in the treatment of B cell
leukemias and lymphomas (Bargou et al., 2008; Sadelain, 2015)tracellular T cell signaling and shows that the dimensions of
efficiency of the synapse formation and subsequent T cell
ell-recruiting therapies. Using this information we developed
notherapy formultiplemyeloma. The anti-FcRH5/CD3 TDB is
bone marrow plasma cells in primates.
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and have demonstrated promising activity in myeloma (Garfall
et al., 2015; Rapoport et al., 2015). Our previous preclinical
studies have validated full-length bispecific antibodies as an
optimal TDB format with favorable drug-like properties including
long serum half-life and low risk for anti-drug antibodies (Junttila
et al., 2014; Sun et al., 2015).
TDBs activate T cells upon ligation with target-expressing
cells resulting in potent target cell killing. However, themolecular
mechanism that induces T cell activation has not been described
in detail. The close proximity of cell membranes forms the basis
of the kinetic segregation model for T cell receptor (TCR) trig-
gering (Davis and van der Merwe, 2006). The model proposes
that the exclusion of inhibitory molecules, such as CD45 phos-
phatase, from regions of close cell-cell apposition causes
increased kinase activity and leads to phosphorylation of pep-
tide-major histocompatibility complex (pMHC)-bound TCRs
within this region. This then initiates receptor triggering and sub-
sequent downstream T cell activation. Exclusion of CD45 from
the synapse has been shown to be a passive process driven
by the large size of the extracellular domain (James and Vale,
2012). If correct, the model predicts that a tumor target with a
large extracellular domain may be suboptimal for synapse for-
mation by CD3-bispecific antibodies. The size of the target pro-
tein has previously been linked to the killing activity of bispecific
T cell engagers (BiTE) (Bluemel et al., 2010).
Given the potential of FcRH5 as a target for antibody-based
therapeutics, the goal of the current study was to develop a
TDB targeting FcRH5 (anti-FcRH5/CD3 TDB) for the treatment
of MM. Moreover, we characterized the molecular events in
the immunological synapse that lead to triggering of the TCR
upon stimulation by CD3-bispecific antibodies.
RESULTS
Anti-FcRH5/CD3 TDB Induces Target Clustering and
Exclusion of CD45 from the Synapse Resulting in TCR
Triggering
We characterized the molecular events in the immunological
synapse that lead to triggering of the TCR upon stimulation by
CD3-bispecific antibodies. To do this, we utilized a recently
described reconstituted system that allows investigation of the
initial events that lead to receptor activation in a controlled
manner. HEK-T cells are non-immune cells that express the min-
imal components of the TCR signaling network required to drive
receptor activation (James and Vale, 2012). Previous studies us-
ing this model have demonstrated that exclusion of CD45 phos-
phatase from the cell-cell interphase is both necessary and suf-
ficient for TCR-pMHC-driven TCR triggering, supporting the
kinetic segregation model (James and Vale, 2012). The HEK-T
cells were conjugated with FcRH5-expressing cells in the pres-
ence of the CD3 bispecific antibody, and the relative intensities
of CD45, FcRH5, and the fluorescently labeled TDB at the conju-
gate interface were imaged by confocal microscopy. ZAP70 is
normally cytosolic but binds to phosphorylated ITAMs on the
TCR when the receptor is bound to pMHC. The translocation
of ZAP70 provides a convenient microscopy-based assay to
evaluate TCR triggering (James and Vale, 2012). TDB binding
to the membrane-proximal immunoglobulin (Ig) domain of
FcRH5 (1G7; Figure 1A) led to efficient synapse formation, a384 Cancer Cell 31, 383–395, March 13, 2017robust clustering of FcRH5 in the cell-cell interaction site, and
exclusion of the CD45 from the synapse (Figure 1B). The com-
bined result of FcRH5 clustering and exclusion of inhibitory mol-
ecules was TCR triggering illustrated by ZAP70 translocation to
the cell interface (Figure 1B).
We then compared the sequence of events in synapse forma-
tion at the cell-cell interface when driven by CD3-bispecific anti-
body binding (Figures 1A and 1B) with those at the interface
caused by the pMHC-TCR interaction itself (Figures 1C and
1D). Overall, the mechanisms leading to TCR triggering,
including target clustering, CD45 exclusion, and ZAP70-translo-
cation, showed remarkable similarity between the CD3-bispe-
cific antibody and pMHC-driven ligation (Figures 1B and 1D).
The interface between the two cells can be visualized by taking
a three-dimensional volume of the cell-cell conjugate formed by
the TDB (Figure 1E). The analysis demonstrated that the segre-
gation of CD45 and the concomitant clustering of FcRH5 caused
by TDB binding extended across the entire interface. The anal-
ysis also demonstrated a spatial mutual exclusion of the
FcRH5 and the CD45 phosphatase. To confirm that this was
the case, we analyzed a line profile across an equivalent inter-
face and quantified the relative intensities of CD45, FcRH5,
and the TDB (Figure 1F). The quantitation of the fluorescent
signal confirmed the strong co-localization between FcRH5
and the TDB, and the complete inverse correlation with CD45
fluorescence intensity. In summary, our results demonstrate
that the CD3-bispecific antibody replicates the mechanism of
the TCR/pMHC interaction-mediated TCR triggering inducing
clustering of the target molecule and exclusion of CD45 from
the T cell synapse resulting in activation of TCR signaling.
CD45 exclusion has been described in the synapse induced by
an Ep-CAM/CD3 BiTE (Offner et al., 2006), demonstrating that
the conjugate interface and the molecular mechanism leading
to T cell triggering share common features despite distinct struc-
tures of these molecules.
A Membrane-Proximal Epitope Is Required for Efficient
Synapse Formation and Killing Activity of the Anti-
FcRH5/CD3 TDB
Similar to CD45, the extracellular domain of FcRH5 is large (550
and 835 amino acids, respectively) allowing us to test the effect
of structural parameters of the tumor target on synapse forma-
tion and killing activity. We generated three proof-of-concept
TDBs that bind to different regions of FcRH5 (Figure 2A). TDB
binding to the membrane-proximal Ig domain of FcRH5 (1G7)
led to synapse formation significantly more efficiently compared
with TDBs targeting central (10A8) or distal domains (gD) of the
target (Figure 2B), driving efficient CD45 exclusion (Figures 2B
and 2C) and target clustering (Figures 2B and 2D) at the cell-
cell interface. The efficiency of forming a synapse was reflected
in the ability of the TDB to induce TCR signaling and mediate
killing by human T cells. Using healthy donor CD8+ T cells,
1G7-TDB resulted in very robust SLP76 phosphorylation (Fig-
ure 2E), which is indicative of potent TCR signaling, and medi-
ated efficient killing of target cells (Figure 2F; median effective
concentration (EC50 = 0.5 nM). In contrast, gD-TDB targeting
of a membrane-distal epitope resulted in undetectable TCR
signaling and was unable to mediate T cell killing. Monovalent
binding affinities of antibodies used (KD = 12 versus 3 nM by
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Figure 1. Anti-FcRH5/CD3 TDB Induces
Target Clustering and Exclusion of CD45
from the Synapse Resulting in TCR Trig-
gering
(A) Schematic of the interface between the FcRH5-
expressing target cell and the reconstituted HEK-T
cell, with protein dimensions shown approximately
to scale. The remaining components of the HEK-T
cells, including the normally cytoplasmic kinase,
ZAP70, have been omitted for clarity.
(B) Representative images of TDB-mediated
conjugates (1G7-TDB) between an FcRH5-ex-
pressing HEK cell and a reconstituted HEK-T cell,
showing CD45 segregation, FcRH5 clustering, and
ZAP70 recruitment at the cell interface.
(C) Schematic of the interface between the pMHC-
expressing target cell and the reconstituted HEK-T
cell, with protein dimensions shown approximately
to scale. The remaining components of the cells,
including the normally cytoplasmic kinase, ZAP70,
have been omitted for clarity.
(D) Representative images of conjugates between
a pMHC-expressing Raji B cell and a reconstituted
HEK-T cell, showing CD45 segregation, pMHC
clustering, and ZAP70 recruitment at the cell
interface.
(E) A reconstructed en face view of a conjugate
interface equivalent to that shown in (B).
(F) Line profiles of CD45 (green), FcRH5 (blue), and
TDB (red) intensities across a conjugate interface
equivalent to that shown in (B). In all images, box
color denotes that used in the overlay image.
Scale bars, 5 mm (B) and (D) or 2 mm (E) in length.Scatchard analysis for 1G7 and 10A8, respectively) do not
explain the differences in the synapse formation or signaling.
We next confirmed that the TDB activity is driven primarily by
the location of the epitope and the size of the extracellular
domain (ECD) by targeting cells that express a heavily truncated
FcRH5 that retains the 1G7 and gD epitopes (Figure 2G). The
activity of the proximal 1G7-TDB increased by 25-fold (Fig-
ure 2H; EC50 = 20 pM) and the gD-TDB was able to effectively
mediate killing of cells (EC50 = 0.19 nM) when the obstruction
caused by the ECD was removed. The possibility of differential
target expression level being the cause for the activity differ-
ence between cell lines was ruled out by flow cytometry (Fig-
ure S1A). To confirm that the differences in the killing activity
are related to the epitope rather than being properties of the
specific TDB clones, we tested a total of five unique antibody
clones targeting the membrane-proximal domain for the
FcRH5 in bispecific format and could demonstrate that the ac-
tivity of each clone was 20-fold higher compared with 10A8
(Figure 2I). These findings were confirmed using the MOLP-2
myeloma cell line, which endogenously expresses FcRH5 at a
low level comparable with that of MM patients. When T cells
were retargeted to kill MOLP-2 cells, only membrane-proximal
TDBs induced killing of the MOLP-2 cells. Targeting the mid re-
gion of FcRH5 would not lead to sufficiently potent TCR trig-
gering to kill MOLP-2 cells (Figure S1B). Together these data
demonstrate that formation of the immunologic synapse by a
CD3-bispecific antibody is dependent on the dimensions ofthe target molecule, and that rational epitope selection based
on membrane proximity can overcome the hindrance caused
by a large target protein that would otherwise lead to subopti-
mal synapse formation.
The Anti-FcRH5/CD3 TDB Induces Target-Dependent
Cell Killing and T Cell Proliferation
The anti-FcRH5 clone 1G7 was humanized and paired with a hu-
manized anti-CD3 arm that is cross-reactive to the cynomolgus
monkey to generate an anti-FcRH5/CD3 TDB. Anti-FcRH5/CD3
TDB is specific to FcRH5 and binds to the membrane-proximal
domain of the target (Figures S2A–S2B). Anti-FcRH5/CD3 TDB
binds to FcRH5-expressing myeloma cell lines (MOLP-2),
healthy donor B cells, bone marrow plasma cells, and primary
myeloma tumor cells (Figure S2C). Preclinical characterization
of anti-FcRH5/CD3 TDB activity to confirm its mechanism of ac-
tion was performed. Treatment of FcRH5-positive MOLP-2 cells
with the anti-FcRH5/CD3 TDB and CD8+ or CD4+ T cells from
healthy donors resulted in dose-dependent T cell activation
and killing of MOLP-2 cells (Figures 3A and 3B). Anti-FcRH5/
CD3 TDB also had an effect on Treg cell activation (Figure S2D).
The cytotoxic activity of TDB required FcRH5 expression on
target cells and the potency correlated with FcRH5 expression
level (Figure 3C). Stimulation of effector T cells with the anti-
FcRH5/CD3 TDB in the presence of target cells led to a robust
proliferation of T cells, with 95% of the CD8+ cells undergoing
as many as six cell divisions in 5 days (Figure 3D).Cancer Cell 31, 383–395, March 13, 2017 385
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Figure 2. Membrane-Proximal Epitope Is Required for Efficient Synapse Formation and Killing Activity of Anti-FcRH5/CD3
(A) Schematic of the epitope locations of the three TDBs used in the figure, including the gD epitope at the N terminus.
(B) Representative confocal images of the interface between aHEK-T cell and an FcRH5-expressing HEK cell, where conjugate formation has been induced using
the indicated fluorescently labeled TDB. The overlay image identifies the cell-cell interface over which the intensities of CD45, FcRH5, and TDB were measured,
relative to the rest of the plasma membrane. Box color denotes that used in the overlay image. Scale bars, 5 mm.
(C) Quantification of CD45 intensity in the conjugate interface relative to CD45 intensity in the rest of the plasma membrane. Data shown are the mean from 12 to
17 conjugates for each TDB is shown ±SEM.
(D) Equivalent quantification of FcRH5 intensity in the same cells used in (C), presented as fold-increase of intensity compared with rest of target plasma
membrane ± SEM.
(E) Phospho-SLP76 western blot of peripheral CD8+ T cells from a healthy donor stimulated with 1 mg/mL TDBs and cells expressing human FcRH5 with an
N-terminal gD expression tag. Total SLP76 is shown to confirm equal sample loading.
(F) FcRH5 target cell killing using either 1G7 (blue) or gD (red) TDBs using CD8+ T cells.
(G) Schematic of the truncated FcRH5 construct with the gD tag now proximal to the membrane.
(H) Target cell killing using the truncated FcRH5 construct using 1G7 (blue) or gD (red) TDBs. The truncated construct was expressed in HEK293 cells.
(I) Target cell killing using 1G7 TDB (blue), alternate TDBs that recognize the membrane-proximal epitope (dashed lines), or 10A8 TDB (green). Data in (F), (H), and
(I) are represented as the mean ± SD. See also Figure S1.Expression of FcRH5 in Normal Tissues and MM
FcRH5 is expressed in the B cell lineage starting from pre-B
cells, but unlike most B cell markers, its expression is retained
in plasma cells (Polson et al., 2006). Analysis of FcRH5 RNA
expression in the Genotype-Tissue Expression (GTEx) sample
set (Ardlie et al., 2015), consisting of 8,555 samples from 544 do-
nors over 53 tissues, demonstrated expression in Epstein-Barr
virus- transformed lymphocytes, spleen, and the terminal ileum
of the small intestine (Figure 4A). The RNA signal detected in
spleen and intestine is likely derived from infiltrating B cells.
Further analysis demonstrated a strong correlation with the
expression profile of known B cell and plasma cell markers
(CD19, CD20, and BCMA; Figure 4B). Overall the selective
expression in B lineage cells and tissues predicts a favorable
safety profile for this target.
Expression of FcRH5 in CD138+CD38+ MM cells and normal
bone marrow plasma cells was evaluated by flow cytometry us-
ing bivalent 1G7 antibody. In all samples tested, all patient-
derived tumor cells, and all normal plasma cells expressed
FcRH5, suggesting 100% prevalence in myeloma (Figure 4C).
Considerable inter-patient variability in expression level was de-
tected in MM samples. Generally, FcRH5 expression levels in tu-386 Cancer Cell 31, 383–395, March 13, 2017mor cells was not significantly elevated compared with normal
plasma cells, suggesting that developing a tumor cell-selective,
normal plasma cell-sparing anti-FcRH5/CD3 TDB may not be
feasible. FcRH5 expression level in normal B cells was observed
to be lower compared with normal plasma cells and MM tumor
cells (Figures 4C and S2C), a similar finding as a previous report
(Elkins et al., 2012). To understand the prevalence of expression
in a broader patient population we performed a bioinformatic
analysis of FcRH5 mRNA expression in CD138-purified plasma
cells from 170 non-treated newly diagnosed MM patients and
6 healthy donors (microarray dataset GSE39754 from the NCBI
Gene Expression Omnibus). All myeloma samples were positive
for FcRH5 RNA (Figure 4D). At the mRNA level, FcRH5 expres-
sion was significantly higher in myeloma samples compared
with healthy donor samples. Expression of FcRH5 was higher
in 155 out of 170 (91%) malignant samples compared with the
highest expression level detected in the normal samples. Only
one clinical value of interest, response to the USP7 inhibitor
P5091, is available for the samples, and there was no significant
correlation between this treatment response and FcRH5 expres-
sion (p = 0.62; ANOVA). The FcRH5 gene is located in the chro-
mosomal breakpoint in 1q21 (Hatzivassiliou et al., 2001).
Figure 3. Anti-FcRH5/CD3 TDB Induces T Cell Activation, Target-Dependent Cell Killing, and T Cell Proliferation
(A) Dose-dependent activation of CD4+ and CD8+ T cells upon stimulation with target cells (MOLP-2) and anti-FcRH5/CD3 TDB detected by flow cytometry
analysis.
(B) Target cell (MOLP-2) killing by anti-FcRH5/CD3 TDB and effector cells (CD4+ or CD8+).
(C) Target-dependent killing by anti-FcRH5/CD3 TDB and flow cytometry (insert) of a parental Fox-NY cell line (green) and clones transfected to express low (blue)
or high level (red) of FcRH5. (A), (B), and (C) Data are represented as the mean ± SD.
(D) Anti-FcRH5/CD3 TDB-induced CD8+ T cell proliferation response (5 days) was detected by measuring carboxyfluorescein succinimidyl ester (CFSE) fluo-
rescence intensity dilution. Only CFSE-labeled human CD8+ T cells and those co-cultured with MOLP-2 ± anti-FcRH5/CD3 TDB (1 mg/mL) are shown. See also
Figure S2.Analysis of20 primary MMbiopsies demonstrated a significant
association between FcRH5RNA expression and 1q21 gain (Fig-
ures 4E–4F), demonstrating that the 1q21 gain can lead to
FcRH5 overexpression in high-risk myeloma patients.
The selective expression for B lineage cells and tissues
predicts a favorable safety profile for this target. Overall, 100%
prevalence in myeloma, the predicted favorable safety profile
and overexpression in high-risk patients indicate FcRH5 as a
promising target for MM.
The Anti-FcRH5/CD3 TDB Mediates Potent Killing of
Normal Plasma Cells and Patient-Derived Primary
Myeloma Cells
The ability of the anti-FcRH5/CD3 TDB to kill plasma cells was
analyzed by targeting bone marrow mononuclear cells (BMMCs)
isolated from bone marrow aspirates of healthy donors (Fig-
ure 5A). Anti-FcRH5/CD3 TDB treatment induced potent dose-
dependent killing of normal plasma cells (EC50 = 85–180 pM).
Similarly robust cytotoxic activity was detected when BMMCs
from MM patients were exposed to the anti-FcRH5/CD3 TDB
(Figure 5B). The anti-FcRH5/CD3 TDB demonstrated near-com-plete and highly potent killing of primary myeloma tumor cells
(EC50 = 60–1,200 pM).
As FcRH5 expression is variable in myeloma (Figures 4C–4D)
and anti-FcRH5/CD3 activity correlated with expression level
(Figure 3C), we investigated whether patients whose tumor cells
expressed low levels of FcRH5would be predicted to respond to
the anti-FcRH5/CD3 TDB. The MOLP-2 myeloma cell line was
identified as a benchmark cell line that has similar expression
levels of FcRH5 as plasma cells and primary MM cells (Fig-
ure 4C). We also identified additional cell lines that express
extremely low levels of FcRH5 and determined the number of
FcRH5 molecules per cell using Scatchard analysis. The 1G7
binding sites in these cell lines ranged from 160 to 2,200
FcRH5 molecules per cell. Even with very low target copy num-
ber, anti-FcRH5/CD3 induced killing of all tested cell lines.
Despite the limited maximal killing seen in the case of one cell
line, EC50 values for all cells were in the pM range (EC50 = 2–
230 pM, Figure 5C). Occupancy calculations indicate that as
few as 50 TDB molecules (2% occupancy at MOLP-2;
EC50 = 58 pM) are sufficient to induce T cell activation and target
cell apoptosis.Cancer Cell 31, 383–395, March 13, 2017 387
Figure 4. Expression of FcRH5 in Normal Tissues and Multiple Myeloma
(A) FcRH5 RNA-seq analysis of the Genotype-Tissue Expression (GTEx) sample set. Boxes represent the interquartile range (IQR, 25th to 75th percentile), the
horizontal line is the median. Whiskers extend to the most extreme data point that is within 1.5*IQR of the 25th and 75th percentiles. Data points beyond the
whiskers represent outliers.
(B) Correlation of FcRH5 expression with CD19, CD20, and BCMA expression in the GTEx samples.
(C) FcRH5 protein expression in primary multiple myeloma tumor cells and healthy donor peripheral B cells and bone marrow plasma cells. FcRH5 expression
was analyzed by flow cytometry normalized to expression in MOLP-2 internal and assay control. Data are represented as the mean ± SEM.
(D) FcRH5 mRNA expression in anti-CD138 purified plasma cells from newly diagnosed non-treated multiple myeloma patients measured using Affymetrix
GeneChip Human Exon 1.0 ST.
(legend continued on next page)
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Figure 5. Anti-FcRH5/CD3 TDB Mediates
Potent Killing of Normal Plasma Cells and
Patient-Derived Primary Myeloma Cells
(A) Cytotoxic activity on human plasma cells was
evaluated by culturing human bone marrow
mononuclear cells (BMMC) for 72 hr with anti-
FcRH5/CD3 TDBs and analyzing the number of live
CD38+CD138+ cells by flow cytometry.
(B) Cytotoxic activity of anti-FcRH5/CD3 TDB
on patient-derived primary myeloma cell was
evaluated by co-culturing human myeloma
BMMCs with CD8+ T cells isolated from healthy
donor and anti-FcRH5/CD3 TDB. The killing ac-
tivity was analyzed as in (A).
(C) The number of anti-FcRH5/CD3 TDB binding
sites per cell was determined using Scatchard
analysis and is indicated in the panel. Cytotoxic
activity of anti-FcRH5/CD3 TDB against target
cells expressing low levels of FcRH5 was assessed
as in (B). Data are represented as the mean ± SD.Anti-FcRH5/CD3 TDB Suppresses Growth of
EstablishedMOLP-2 Tumors in Mice Reconstituted with
Human Immune Cells
Modeling anti-myeloma activity of the anti-FcRH5/CD3 TDB in
mice is challenging since anti-CD3 antibodies do not cross-react
with mouse CD3 and there is no mouse FcRH5 ortholog. There-
fore we established a mouse model with a reconstituted human
immune system by transplanting CD34+-selected human he-
matopoietic stem cells into irradiated mice (humanized NOD/
SCID gamma [huNSG] mice). Human CD8+ cells harvested
from spleens of huNSG mice were shown to be able to kill
MOLP-2 cells in vitro with comparable efficiency as human pe-
ripheral CD8+ T cells from healthy donors (Figure 6A). Twenty
weeks post transplantation, huNSG mice were inoculated with
20 million MOLP-2 cells subcutaneously. Mice with established
tumors (100–200 mm3) were treated with a weekly intravenous
dose of vehicle or 0.5 mg/kg of anti-FcRH5/CD3 TDB. Anti-
FcRH5/CD3 TDB treatment resulted in tumor regression in all an-
imals (Figure 6B), indicating that anti-FcRH5/CD3 suppresses
tumor growth in vivo.Cynomolgus Monkey Is an Appropriate Preclinical
Model for the Anti-FcRH5/CD3 TDB
Flow cytometry analysis was used to confirm both the reactivity
of anti-FcRH5 1G7 to FcRH5 and expression of the target in B
cells and plasma cells in cynomolgus monkey (Figures S3A–
S3C). FcRH5 expressionwas detected throughout the B cell line-(E) qRT-PCR analysis of FcRH5 mRNA level in bone marrow biopsies from patient myeloma samples with
calculated by the delta Ct (dCt) method. Statistical analysis was performed using a Mann-Whitney U test. T
median. Whiskers represent the range of minimum and maximum values.
(F) Representative images of FISH analysis on primary multiple myeloma biopsies showing normal diploid o
copies of 1q21 (bottom). A tumor sample was identified as 1q21 gain when >20% of the tumor cells scored h
bars, 10 mm in length.
Caage in a similar manner to human (Polson
et al., 2006), and the anti-FcRH5/CD3
TDB binds to FcRH5 and CD3 with com-parable affinity. Treatment with anti-FcRH5/CD3 TDB of target
cells expressing primate FcRH5 or MOLP-2 cells expressing
human FcRH5 resulted in robust killing using peripheral T cells
from either human or cynomolgus monkey with comparable effi-
ciency (Figures S3D and S3E). Adding anti-FcRH5/CD3 TDB to
peripheral blood mononuclear cell (PBMC)/BMMC samples
from cynomolgus monkey also resulted in a dose-dependent
and robust killing of B cells (Figure S3F) and bone marrow
plasma cells (Figure S3G). These results validate the cynomol-
gus monkey as an appropriate safety and efficacy model for
the anti-FcRH5/CD3 TDB.
Anti-FcRH5/CD3 TDB Has a Long Serum Half-Life in
Cynomolgus Monkeys
A single-dose study was conducted to evaluate efficacy, phar-
macokinetic (PK) and pharmacodynamic (PD) properties of the
anti-FcRH5/CD3 TDB in cynomolgus monkeys. Monkeys were
treated with a single intravenous dose with slow infusion of
vehicle or 1, 2, or 4 mg/kg of anti-FcRH5/CD3 TDB. Blood
samples were collected for analysis of PK/PD response and
cytokines for 7 days after the anti-FcRH5/CD3 TDB was admin-
istered. The study was terminated at day 8.
The anti-FcRH5/CD3 TDB demonstrated dose-proportional
exposure (Cmax and area under the curve) between 1 and
4 mg/kg and with clearance ranging from 29 to 33 mL/day/kg
in all cohorts (Figure 7A). The Cmax at the 4 mg/kg dose level
was 129 mg/mL, 2,000-fold higher than that required to reachor without 1q21 gain. mRNA expression level was
he box represents the 25th to 75th percentiles and
f 1q21 (red; top panel) and a mixture of three to six
ad three or more copies of the 1q21.3 locus. Scale
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Figure 6. Anti-FcRH5/CD3 TDB Suppresses
Growth of Established MOLP-2 Tumors in
Mice Reconstituted with Human Immune Cells
(A) MOLP-2 killing activity of peripheral T cells from
healthy human donors and of human CD8+ T cells
isolated from spleens of humanized NOD/SCID
gamma (huNSG) mice. Data are represented as the
mean ± SD.
(B) The mice were treated with a weekly intrave-
nous dose of vehicle or anti-FcRH5/CD3 TDB at
0.5 mg/kg. The individual tumor volumes (gray),
mean tumor volume (blue bold line in the vehicle-
treated group; black bold line in the anti-FcRH5/
CD3 TDB-treated group), and mean of control
group (blue dashed line) are shown.the in vitro killing EC50 for human plasma cells and MOLP-2. Re-
ceptor occupancy calculations suggested near-total saturation
of FcRH5 engagement on peripheral blood B cells at Cmax at all
dose levels (Figure S4A). In summary, these results demonstrate
that the anti-FcRH5/CD3 TDB has PK characteristics that sup-
port an intermittent weekly or less frequent dosing schedule.
Anti-FcRH5/CD3 TDB Depletes B Cells and Bone
Marrow Plasma Cells in Cynomolgus Monkeys
Flow cytometry of peripheral blood demonstrated a robust phar-
macologic effect at all dose levels. Anti-FcRH5/CD3 treatment
resulted in T cell activation and a transient decrease in T cells
likely reflecting a margination response within 24 hr (Figures
7B, 7C, S4B, and S4C). CD4+ and CD8+ T cells recovered to
baseline levels by the end of the study. In contrast, B cells re-
mained to be undetectable in blood 7 days after anti-FcRH5/
CD3 TDB administration indicating that they were depleted by
exposure to the molecule (Figure 7D). All dose levels resulted
in complete depletion of B cells in spleen and bone marrow (Fig-
ures 7E and 7F). Anti-FcRH5/CD3 TDB treatment also induced a
robust, dose-dependent depletion of B cells from the lymph no-
des (Figures 7G and S4D).
Depletion of primate bone marrow plasma cells is a key effi-
cacy endpoint in the preclinical development of the anti-
FcRH5/CD3 TDB. Complete depletion of plasma cells following
anti-FcRH5/CD3 TDB treatment was observed in the animals
treated at 2 and 4mg/kg (Figure 7H). Anti-FcRH5/CD3 treatment
also resulted in a dose-dependent reduction of IgG of 37% and
44% in the 2 and 4 mg/kg groups, respectively (Figure 7I), an ex-
pected secondary outcome resulting from plasma cell depletion.
These figures compare favorably with calculations based on the
half-life of IgG suggesting that complete depletion of plasma
cells would decrease IgG level 30%–40% by day 7. In sum-
mary, anti-FcRH5/CD3 TDB induced a robust PD response in
cynomolgus monkeys consistent with its mechanism of action.
Complete plasma cell depletion with subsequent decrease in
serum IgG levels provides compelling evidence of TDB activity
in the bone marrow microenvironment.
Anti-FcRH5/CD3 TDB Induces Transient Cytokine
Release in Cynomolgus Monkey
Consistent with the mechanism of action, treatment with the
anti-FcRH5/CD3 TDB at all dose levels tested induced a rapid,
generally mild/moderate cytokine release (Figure S5), including390 Cancer Cell 31, 383–395, March 13, 2017elevations in IL-6, IL-5, IFN-g, IL-2, IL-13, and MCP-1 as well
as the anti-inflammatory response peaking at 2–6 hr. All cyto-
kines returned to normal baseline levels within 24 hr. In summary,
no signs of severe or prolonged cytokine release were observed
at dose levels that are expected to saturate target and sufficient
for complete depletion of B cells and plasma cells. A single dose
at the %4 mg/kg dose level did not result in detectable
neurotoxicity.
PD-L1 Blockade Enhances the Activity of Anti-FcRH5/
CD3 TDB
A strong TCR stimulation signal normally leads to immunosup-
pressive feedback that limits T cell activity. Signaling through
the PD-1/PD-L1 axis is a critical component of this feedback
and a therapeutically validated immune escape mechanism in
several tumor indications. PD-L1 is frequently expressed by
myeloma cells (Gorgun et al., 2015), and the signaling axis may
limit T cell activity in myeloma patients.
In vitro stimulation (48 hr) of human healthy donor CD8+ cells
with anti-FcRH5/CD3 TDB in the presence of target-expressing
cells resulted in significant PD-1 induction in T cells (Figure 8A).
This feedback signal was also observed in vivo. A significant in-
crease in the number of PD-1-positive T cells was observed
when cynomolgus monkeys were treated with anti-FcRH5/CD3
TDB at all tested dose levels. PD-1 induction was detected in
both CD8+ and CD4+ T cells in blood, spleen, lymph nodes, and
bone marrow (Figures 8B and S6). The ability of anti-FcRH5/
CD3 TDB-primed CD8+ T cells to kill PD-L1-expressing target
cells was modest (Figure 8C); however, blocking PD-1/PD-L1
signaling using an anti-PD-L1 antibody in combination with anti-
FcRH5/CD3 significantly increased the efficiency of killing (Fig-
ure 8C). Together, these results show that anti-FcRH5/CD3
TDB-mediated activation of T cells leads to induction of PD-1 in
T cells in vitro and in vivo. Although PD-1/PD-L1 signaling can
limit anti-FcRH5/CD3 TDB-mediated killing, PD-L1 blockade
can overcome this inhibition and lead to enhanced activity of
the anti-FcRH5/CD3 TDB. Our data provide strong scientific
rationale for the clinical assessment of anti-FcRH5/CD3 TDB
combined with anti-PD-L1 blockade in MM patients.
DISCUSSION
Several CD3-bispecific antibodies or antibody fragment-
based molecules are in clinical development and clinical
Figure 7. Anti-FcRH5/CD3 TDB Depletes B Cells and Bone Marrow Plasma Cells in Cynomolgus Monkey
A single intravenous dose of vehicle (blue) or anti-FcRH5/CD3 TDB (red, 1 mg/kg; brown, 2 mg/kg; green, 4 mg/kg) was administered to three cynomolgus
monkeys/group.
(A) Blood samples were collected at indicated time points and human IgG was detected by ELISA.
(B and C) The effect of anti-FcRH5/CD3 TDB on CD4+ (B) and CD8+ (C) T cell activation in peripheral blood.
(D–G) The absolute count of CD20+ B cells in peripheral blood (D), spleen (E), bone marrow (F), and mandibular lymph node (G).
(H and I) The effect of anti-FcRH5/CD3 TDB on bone marrow plasma cells (H) and serum IgG (I) levels. The difference between before and after treatment was
analyzed by unpaired t test. Data in E–I are represented as the mean ± SEM. See also Figures S3–S5.
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Figure 8. PD-L1 Blockade Enhances Activ-
ity of Anti-FcRH5/CD3 TDB
(A) CD8+ T cells were stimulated for 48 hr with
1 mg/mL anti-FcRH5/CD3 TDB and MOLP-2 target
cells, and analyzed by flow cytometry for the PD-1
expression.
(B) The percentage of PD-1+ cells in CD8+ T cells in
cynomolgus monkeys after single-dose intrave-
nous administration of vehicle (blue), 1mg/kg (red),
2 mg/kg (brown), and 4 mg/kg (green) of anti-
FcRH5/CD3 TDB. Individual animal data are
shown.
(C) The ability of anti-FcRH5/CD3 TDB to redirect
activity of pre-stimulated CD8+ T cells (A) to kill
293-FcRH5-PD-L1 cells was tested in the pres-
ence (blue) or absence (red) of 10 mg/mL anti-PD-
L1. Data are represented as the mean ± SEM. See
also Figure S6.proof-of-concept has been established by blinatumomab in he-
matological malignancies (Bargou et al., 2008). Optimally, the
CD3-bispecific molecules show extremely potent preclinical ac-
tivity regardless of the target molecule or the molecule format. In
our studies, using a plethora of tumor targets and antibody
clones, we have detected extreme variability in the activity of
the molecules that could not explained by the affinities of the
molecules. In this study we describe the molecular events in
the synapse induced by a CD3-bispecific full-length antibody
and show that the events closely follow the principles of kinetic
segregation, and are not significantly different compared with
TCR activation by pMHC ligation. Our studies confirm that
FcRH5 is suboptimal for bispecific antibody-mediated T cell trig-
gering due to its large ECD that interferes with efficient synapse
formation. By using antibodies that bind to various different epi-
topes we show that the efficiency of synapse formation corre-
lates with the proximity of binding epitope to cell membrane.
The difference between the epitopes in the end result (killing of
myeloma cells) is dramatic: membrane-proximal antibodies kill
with picomolar concentrations, whereas more distal antibodies
are essentially inert. Potency in the context of BiTE-mediated
killing has been correlated with similar structural features of the
target molecule (Bluemel et al., 2010) complementing our molec-
ular studies of synapse and mechanism of T cell triggering.
Anti-FcRH5/CD3 TDB killed patient-derived myeloma cells
and healthy donor-derived plasma cells at picomolar concentra-
tions. Non-clinical pharmacology studies with anti-FcRH5/CD3
TDB in mice are challenging. First, anti-FcRH5/CD3 TDB is not
reactive to mouse CD3. Second, an FcRH5 ortholog does not
exist in the mouse; thus genetically engineered mouse models
are not suitable for testing the molecule. The only available
mouse tumor model that can be used is human myeloma cell
line (MOLP-2) xenografted to immune-compromised mice sup-
plemented with human T cells. As these tumors are grafted sub-
cutaneously, the MOLP-2 xenografts do not model activity in the
bone marrow environment. A further clear limitation of this type
of xenograft model is that the immune system engrafted in the
mice likely does not exactly recapitulate the adult human im-392 Cancer Cell 31, 383–395, March 13, 2017mune system, potentially not accounting for the contribution of
other cell types, such as Treg cells, to TDB treatment. In contrast,
cynomolgus monkeys can be used as a compelling efficacy
model to demonstrate in vivo activity in the bone marrow
compartment. A single dose of the anti-FcRH5/CD3 TDB
depleted plasma cells and B cells from tissues and led to ex-
pected reduction of serum IgG levels.
Cytokine release has been reported consistently across CD3-
targeting bispecific molecule platforms with variable frequency
and severity. Clinical cytokine release syndrome (CRS) has
been reported in CD19-targeting agents, e.g., blinatumomab
and CD19 CAR-T cells. As expected, the anti-FcRH5/CD3 TDB
induced mild/moderate cytokine release immediately after
dose administration, but no extensive or prolonged cytokine
release was observed in cynomolgus monkeys. The predictive
value of the detected cytokine levels in primates to CRS in
myeloma patients is unclear. However, several potential mitiga-
tion strategies are available for cytokine-related adverse effects
(dose fractionation, corticosteroids, or IL-6 signaling blockers).
The anti-FcRH5/CD3 TDB is predicted to be broadly active in
myeloma as the prevalence of the target expression is 100%,
and as few as 200 copies of FcRH5 on a MM cell are sufficient
to induce tumor cell killing. In addition to myeloma, evidence of
frequent FcRH5 expression has been reported in multiple B
cell malignancies such as chronic lymphocytic leukemia, mantle
cell lymphoma, diffuse large B cell lymphoma, and follicular lym-
phoma (Ise et al., 2007; Li et al., 2008; Polson et al., 2006). This
suggests a more general applicability for anti-FcRH5/CD3 in B
cell-mediated malignancies in addition to MM.
Gain or amplification of chromosome 1q21 is one of the most
commonly detected genetic abnormalities in MM and is consid-
ered a predictive marker of aggressive disease (Boyd et al.,
2012). FcRH5 was originally identified in cloning of this chromo-
somal region and has been shown to be deregulated in cell lines
with 1q21 abnormalities (Hatzivassiliou et al., 2001). Our analysis
of primarymyeloma samples demonstrates that FcRH5mRNA is
elevated in myeloma patients with 1q21 gain. Although it is un-
likely that FcRH5 plays a functional role in the myeloma
progression, its overexpression provides an intriguing diagnostic
hypothesis for the anti-FcRH5/CD3 TDB. Our in vitro assays
demonstrate a correlation between target expression level and
activity of the molecule, suggesting that MM with gain of 1q21
may be exquisitely sensitive to the anti-FcRH5/CD3 TDB, thus
providing clinical benefit to a patient population that otherwise
has very limited treatment options.
T cell activation by anti-FcRH5/CD3 TDB induced upregula-
tion of PD-1 in T cells. This negative feedback signaling has
been detected with other CD3 targeting bispecific molecules
regardless of the format of the molecule (Bacac et al., 2016;
Junttila et al., 2014; Osada et al., 2015), and is likely a class effect
for molecules with this mechanism of action. As PD-1/PD-L1
signaling can inhibit the killing activity of T cells, optimal clinical
use of T cell-recruiting bispecific antibodies may include combi-
nation with inhibitors for this pathway.
EXPERIMENTAL PROCEDURES
Antibodies
Antibodies were from BD Biosciences unless otherwise mentioned. Anti-hu-
man PD-1 was from Affymetrix. Goat anti-human IgG and goat anti-mouse
IgG were from Jackson ImmunoResearch. Anti-PC-FITC (clone Vs38c) was
from Dako. SLP-76 from Cell Signaling Technology. p-SLP76 (Ser376) and
anti-PD-L1 antibodies were generated at Genentech.
Fluorescent Labeling of Antibodies
For detection of FcRH5 from MM samples and healthy donor plasma and B
cells by flow cytometry, anti-FcRH5 antibody 1G7 was labeled with phycoer-
ythrin by SouthernBiotech. For microscopy, the TDBs were labeled with Alexa
Fluor 647 using the appropriate protein labeling kit (Thermo Fisher Scientific)
according to the manufacturer’s instructions. TDBs were dialyzed into PBS,
pH 7.2, prior to labeling and a dye/protein ratio of 4 was routinely achieved.
Stable Cell Lines
To evaluate the immunological synapse formation, SVT2 cells were infected
with retrovirus encoding full-length FcRH5 with N-terminal gD expression
tag or truncated FcRH5 (deletion of AA1-744) with N-terminal gD tag. To eval-
uate the target dependency of TDB killing, FOX-NY cells were infected with
lentivirus encoding full-length FcRH5 and single-cell-derived clones with dif-
ferential expression level of FcRH5 were selected. To evaluate the effect of
PD-1/PD-L1 signaling to TDB activity, 293 cells were infected with lentivirus
encoding FcRH5 followed by transfection of human PD-L1 encoding plasmid
using Lipofectamine (Invitrogen).
Vectors and Transient Transfection for Microscopy
FcRH5 with N-terminal gD expression tag was fused to the fluorescent protein
mRuby2 by first inserting FcRH5 into the pHR-SIN lentiviral vector, before
ligating the mRuby2 DNA sequence into this vector, creating pHR-FcRH5-
mRuby2. The SFFV promoter in this vector was subsequently replaced with
the mHSP promoter, creating pHRI-FcRH5-mRuby2, which utilizes a weaker
promoter than pHR, allowing more physiological expression levels of
FcRH5-Ruby. Vectors expressing LCK, ZAP70, CSK/CBP, and CD45 have
been described previously (James and Vale, 2012). The CD45 construct
used was either the RO isoform or a construct containing the cytoplasmic
domain of CD45 with the transmembrane and ECDs of CD43, which is known
to mimic the function of CD45. Vectors were transiently transfected at appro-
priate ratios using GeneJuice (Novagen), Cells were used in experiments 24–
48 hr after transfection.
Microscopy Imaging and Analysis
To image cell conjugates, 3 3 105 cells were harvested from culture and
resuspended in 100 mL of 20 nM TDB in RPMI-1640 (without phenol red). After
20–30 min incubation to allow cell conjugation, cells were washed with PBS,
resuspended in DMEMgfp2 imaging medium (Evrogen) and added to 35 mmimaging dishes (Mattek). An Andor spinning disc confocal microscope system
was used to image the cells at 37C. All images were analyzed and all pre-
sented images were manipulated in an equivalent manner using ImageJ. The
presented images were background subtracted and then cropped to focus
on the pair of cells and the contrast was optimized. The degree of protein clus-
tering and segregation was determined by using the intensity of fluorescently
labeled proteins in the plasma membrane. The plasma membrane was
selected by manually drawing a line and the average fluorescence intensity
of the plasma membrane within the cell-cell interface was divided by the
average fluorescence intensity of the plasma membrane outside the cell-cell
interface to calculate the degree of clustering or segregation. To generate an
image of the interface of a pair of cells conjugated by TDBs from a z stack,
the image stack was first deconvolved and then cropped to highlight the inter-
face region using Huygens software.
Production of TDBs
Full-length bispecific antibodies were produced as described elsewhere (Junt-
tila et al., 2014; Sun et al., 2015). In brief, the two half antibodies containing the
‘‘knob’’ or the ‘‘hole’’ mutations in the CH3 domains were expressed by tran-
sient transfection of CHO cells and then affinity purified with Protein A. Equal
amounts of the two half antibodies were incubated with a 200 molar excess of
reduced glutathione at pH 8.5 overnight at 32C to drive the formation of the
knob-hole disulfide bonds. The assembled bispecific antibody was purified
from contaminants through hydrophobic interaction chromatography.
In Vitro Cytotoxicity Assays: Cell Lines
PBMCs and CD8+ separation, CellTiter-Glo (Promega) and flow cytometry-
based viability assays (48 hr) were described previously (Junttila et al.,
2014). CD4+ T cells were isolated fromPBMCs by the Human CD4+ T cell Isola-
tion Kit (Miltenyi Biotec). CD4+ or CD8+ cells were used as effectors in a 3:1
effector:target ratio.
In Vitro Cytotoxicity Assay: Human Plasma Cells and Primary MM
Samples
Human BMMCs from MM patients were procured from Conversant Bio.
Human bone marrow aspirates of healthy donors were procured from AllCells.
All human biospecimens were collected, processed, and distributed in full
ethical and regulatory compliance with the sites from which human bio-
specimens were collected. This includes independent ethical review, institu-
tional review board approval (where appropriate), independent regulatory
review, and ethical review for collection sites. All sites were located in the
US and the EU. In vitro experiments using human healthy donor blood, bone
marrow, or vendor-procured live tumor material are routinely performed at
Genentech and do not require approval by an internal ethical review
committee.
Human bone marrow aspirates of healthy donors were diluted in PBS and
BMMCs were isolated by conventional gradient separation (Lymphoprep,
STEMCELL). Flow cytometry viability assay was used to test the effect of
72 hr anti-FcRH5/CD3 TDB treatment on BMMC plasma cells. Myeloma
BMMCs were mixed with freshly isolated healthy donor CD8+ T cells and
co-culture treated with anti-FcRH5/CD3 TDB for 72 hr. PI-negative
CD38+CD138+ cells were counted by flow cytometry. The killing activity was
calculated as: {(number of live target cells without TDB number of live target
cells with TDB)/(number of live target cells without TDB)} 3 100%.
T Cell Activation
Human CD4+ T cells, CD8+ T cells, or Treg cells (CD4
+CD25+CD127low) were
mixed with MOLP-2 cells in a 3:1 ratio and co-cultured with Anti-FcRH5/
CD3 TDB for 24 hr. The T cell activation assay has been described previously
(Junttila et al., 2014).
T Cell Proliferation
CD8+ T cells were labeled with carboxyfluorescein succinimidyl ester and co-
cultured with MOLP-2 cells (1:1) and 1 mg/mL TDB for 5 days.
Western Blot Analysis
pSLP76 (Ser376) and SLP76were analyzed in human CD8+ T cells co-cultured
with HEK293-FcRH5 cells (2:1) and 1 mg/mL of TDBs.Cancer Cell 31, 383–395, March 13, 2017 393
RNA Expression in Normal Tissues and Myeloma Samples
mRNA expression was analyzed in the GTEx RNA sequencing sample set (Ar-
dlie et al., 2015) consisting of 8,555 samples from 544 donors over 53 tissues
and in the NCBI GEO: GSE39754 dataset (Affymetrix GeneChip Human Exon
1.0 ST Array) from the NCBI GEO repository (Chauhan et al., 2012). CD138 pu-
rified plasma cell samples in the NCBI GEO: GSE39754 dataset represent
newly diagnosed patients with MM before initiation of primary treatment.
RNA Isolation, cDNA Synthesis, and Gene Expression Analysis
Total RNA was extracted from decalcified formalin-fixed paraffin-embedded
(FFPE) bonemarrow biopsy tissues collected fromMMpatients. Two reference
genes, SDHA and VPS33B, were evaluated for each sample and used to calcu-
late expression of FcRH5. Gene expression of FcRH5was determined by using
the delta Ct (dCt) method (Ctgene of interest – Ctgeometric mean of reference genes).
Detailed description of method in the supplement.
Cytogenetic Fluorescent In Situ Hybridization
1q21 + copy control 1 fluorescent in situ hybridization (FISH) probe (Biocare
Medical; previously CymoGen Dx) was used to analyze the 1q21 region. The
1q21 probe covers the chromosomal band 1q21.3 while the control probe is
located in the peri-centromeric 1p12 region of chromosome 1. FISH analysis
on FFPE tissue was performed as described previously (Koeppen et al.,
2014; O’Brien et al., 2008). A minimum of 100 non-overlapping tumor cells
from each sample was enumerated. Cutoff of gain was 3 or more copies in
>20% of the tumor cells. Detailed description of method in the supplement.
huNSG/MOLP-2 Mouse Xenograft Model
All mouse experimental procedures conformed to the guiding principles of the
American Physiology Society and were approved by Genentech’s Institutional
Animal Care and Use Committee (IACUC). Female huNSGmice were obtained
from The Jackson Laboratory. Animals were inoculated with 20 million
MOLP-2 tumor cells in Hank’s balanced salt solution/Matrigel, subcutane-
ously. Treatments were administered intravenously once a week 34. Detailed
description of method in the supplement.
Cynomolgus Monkey Study
The PK and PD properties of anti-FcRH5/CD3 TDB were evaluated in naive,
male cynomolgusmonkeys (cynos) at Charles River Laboratories (CRL). Cynos
were treated with a single-dose, intravenous infusion (1 hr) of vehicle, 1, 2, or
4 mg/kg anti-FcRH5/anti-CD3 TDB blood samples were collected by veni-
puncture via the femoral vein pre-study and at selected time points for
7 days after dosing for analyses of hematology, serum chemistry, coagulation,
and PK and PD endpoints (cytokines, flow cytometry of T lymphocytes, B lym-
phocytes, activated T lymphocytes, and PD-1 and circulating cyno IgG). Bone
marrow was collected in anesthetized animals by aspiration from the humerus
pre-study and on day 8 for evaluation of B lymphocytes and plasma cells by
flow cytometry. The study was terminated at day 8. All procedures were
approved by the CRL IACUC and were performed in compliance with the An-
imal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and
the Office of Laboratory Animal welfare.
Anti-FcRH5/CD3 Pharmacokinetics in Cyno
Anti-FcRH5/CD3 TDB in serum were determined by generic ELISA. Sheep
anti-human IgG antibody was used as the capturing reagent and sheep anti-
human IgG conjugated to horseradish peroxidase (HRP) was used as the
detection reagent. Serum concentration-time data from available samples
were analyzed by a non-compartmental with IV bolus input model (Phoenix
WinNonlin, Version 6.3; Pharsight Corporation). Nominal sample collection
time and nominal dose concentrations were used in the data analysis. All TK
analyses were based on individual animal data.
Flow Cytometry Analysis for Cyno Plasma Cells
Cyno bone marrow aspirate were diluted (1:10) into ammonium-chloride-po-
tassium lysis buffer twice. Cyno bone marrow cells were stained with
anti-CD45, anti-CD20, and anti-CD38. After wash, cells were fixed and per-
meabilized with IntraStain Kit (Dako). Cells then were stained with anti-PC
(clone Vs38c). The cyno plasma cells were classified by flow cytometry as
CD45CD20CD38+PC+.394 Cancer Cell 31, 383–395, March 13, 2017ELISA Analysis for Cyno IgG Level
Total cyno serum IgG was quantified using standard colorimetric-based sand-
wiched ELISA. A goat anti-monkey IgG (Bethyl Laboratories, A140-202A) and
a HRP conjugated goat anti-monkey IgG (Bethyl Laboratories, A140-202P)
were used as the capture and detection antibody, respectively. Cyno IgG
(Cell Sciences CSI20163A) was used as the protein quantification standard.
PD-1 Induction and Cytotoxicity Assay with anti-PD-L1
Human CD8+ T cells and MOLP-2 cells were co-cultured (1:1) with
1,000 ng/mL of TDB for 48 hr and stained with anti-PD-1-APC. Cytotoxicity
assay is described above.
SUPPLEMENTAL INFORMATION
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